020757___S019

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville MD 20857

NDA 20-757/S-019

Bristol-Myers Squibb Company
Attention: Melody A. Brown
P.O. Box 5400
Princeton, NJ 08543-5400

Dear Ms. Brown:

Please refer to your supplemental new drug application dated October 30, 2000, received October 31, 2000, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Avapro (irbesartan) Tablets, 75 mg, 150 mg and 300 mg.

This "Changes Being Effected in 30 days" supplemental new drug application provides for [ ] is an alternative manufacturer of the [ ] used in the synthesis of irbesartan.

We have completed the review of this supplemental application, and it is approved. Please note for future reference that [ ] in the synthesis of the drug substance, irbesartan, and not [ ] as stated in your supplemental application.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Edward Fromm, Regulatory Project Manager, at (301) 594-5313.

Sincerely,

/S/

{See appended electronic signature page}

Kasturi Srinivasachar, Ph.D.
Chemistry Team Leader, DNDC I for the
Division of Cardio-Renal Drug Products, (HFD-110)
DNDC I, Office of New Drug Chemistry
Center for Drug Evaluation and Research

cc:
Sanofi-Synthelabo, Inc.
Attention: Gregory Torre, Ph.D., J.D.
90 Park Avenue
New York, NY 10016

/s/

Kasturi Srinivasachar
3/6/01 05:16:45 PM

DIVISION OF CARDIO-RENAL DRUG PRODUCTS
Review of Chemistry, Manufacturing, and Controls

CHEMIST'S REVIEW	1. **ORGANIZATION** HFD - 110	2. **NDA Number** 20-757
3. **Name and Address of Applicant (City & State)** Bristol-Myers Squibb Company P. O. Box 5400 Princeton, NJ 08543-5400		4. **Supplement(s)** **Number(s) Date(s)** SCM-019 10/30/00
5. **Drug Name** Avapro	6. **Nonproprietary Name** Irbesartan	7. **Amendments &** Other (reports, etc) - Dates
7. **Supplement Provides for:** CHANGES BEING EFFECTED IN 30 DAYS [ ] an alternative manufacturer of the [ ], as the synthesis of the irbesartan.		[ ] used in
9. **Pharmacological Category** Angiotensin II Receptor Antagonist/Hypertension	10. **How Dispensed** /x/ RX /__/ OTC	11. **Related IND(s)/ NDA(s)/DMF(s)** NDA 20-758
12. **Dosage Form(s)** Tablets	13. **Potency(ies)** 75 mg, 150mg, and 300 mg.	
14. **Chemical Name and Structure** 2-Butyl-3-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl) methyl]-1,3-diazaspiro[4.4]non-1-en-4-one.		15. **Records/Reports** Current /x/ Yes /__/ No Reviewed /x/ Yes /__/ No
16. **Comments:** CBE in 30 Days Supplement, Effective Date December 1,2000.		
17. **Conclusions and Recommendations:** The changes reported in the manufacturing process involve different site with no change in the synthesis route. Such supplements can be accepted as a CBE in 30 days and the supplement is recommended for approval.		
18. **REVIEWER**		
Name Ramsharan D. Mittal	**Signature**	**Date Completed** 03/2/01
19. Distribution: /__/ Original Jacket /__/ Reviewer /__/ Division File /__/ CSO		

2 Page(s) Withheld

✓ § 552(b)(4) Trade Secret / Confidential

_____ § 552(b)(5) Deliberative Process

_____ § 552(b)(5) Draft Labeling

/s/

Ramsharan Mittal
3/5/01 01:09:47 PM
CHEMIST

Kasturi Srinivasachar
3/5/01 06:04:30 PM
CHEMIST

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service
Food and Drug Administration
Rockville MD 20857

NDA 20-757/S-019

Sanofi-Synthelabo, Inc.
c/o Bristol-Myers Squibb Pharmaceutical Research Institute
Attention: Ms. Melody A. Brown
P.O. Box 5400
Princeton, NJ 08543-5400

Dear Ms. Brown:

We acknowledge receipt of your supplemental application for the following:

Name of Drug: Avapro (irbesartan) Tablets

NDA Number: 20-757

Supplement Number: S-019

Date of Supplement: October 30, 2000

Date of Receipt: October 31, 2000

Unless we find the application not acceptable for filing, this application will be filed under Section 505(b)(1) of the Act on December 30, 2000 in accordance with 21 CFR 314.101(a).

All communications concerning this NDA should be addressed as follows:

Center for Drug Evaluation and Research
Division of Cardio-Renal Drug Products, HFD-110
Office of Drug Evaluation I
Attention: Document Control Room 5002
5600 Fishers Lane
Rockville, MD 20857

Sincerely,

/S/

Natalia A. Morgenstern
Chief, Project Management Staff
Division of Cardio-Renal Drug Products, HFD-110
Office of Drug Evaluation I
Center for Drug Evaluation and Research

cc:
Original NDA 20-757/019
HFD-110/Div. Files
HFD-110/CSO/Edward Fromm

Filename: G:\PM Folder\NDA ltrs\20757s19.doc

SUPPLEMENT ACKNOWLEDGEMENT

/s/

Natalia Morgenstern
12/14/00 05:56:24 PM